Skip to search formSkip to main contentSkip to account menu

WWTR1 wt Allele

Known as: DKFZP586I1419, TAZ, WW Domain Containing Transcription Regulator 1 wt Allele 
Human WWTR1 wild-type allele is located within 3q23-q24 and is approximately 183 kb in length. This allele, which encodes WW domain-containing… 
National Institutes of Health

Related topics

Related topics

8 relations
3q24Epithelioid hemangioendotheliomaHomo sapiensTranscriptional Activation

Broader (1)

TAZ gene

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2020
2020
Effectiveness comparison and incremental cost-per-responder analysis of calcipotriene 0.005%/betamethasone dipropionate 0.064% foam vs. halobetasol 0.01%/tazarotene 0.045% lotion for plaque psoriasis…
Abstract Background: The fixed-dose combination foam formulation of calcipotriene 0.005% plus betamethasone dipropionate 0.064… 
2019
2019
Halobetasol 0.01%/Tazarotene 0.045% Fixed-combination Lotion in the Treatment of Plaque Psoriasis: Sensitization and Irritation Potential.
Background: Psoriasis is a chronic inflammatory skin disorder often managed with topical therapy. However, the most widely used… 
2019
2019
Nuclear TAZ activity distinctly associates with subtypes of non-small cell lung cancer.
2017
2017
Role of TAZ in Lysophosphatidic Acid-Induced Migration and Proliferation of Human Adipose-Derived Mesenchymal Stem Cells
Transcriptional co-activator with a PDZ-binding motif (TAZ) is an important factor in lysophosphatidic acid (LPA)-induced… 
2015
2015
Efficacy of two-time prophylactic intravenous administration of tazobactam/piperacillin for transrectal ultrasound-guided needle biopsy of the prostate
2015
2015
[Expression of transcriptional coactivator with PDZ-binding motif (TAZ) in colon cancer tissues and its clinical significance].
OBJECTIVE To investigate the expression of transcriptional coactivator with PDZ-binding motif(TAZ) in colon cancer tissues and… 
2012
2012
Investigation of the clinical breakpoints of piperacillin–tazobactam against infections caused by Pseudomonas aeruginosa
The pharmacokinetics–pharmacodynamics (PK–PD) breakpoint of piperacillin/tazobactam (PIPC/TAZ) for hospital-acquired pneumonia… 
2007
2007
Tolerability of piperacillin/tazobactam in children and adolescents after high dose radio-/chemotherapy and autologous stem cell transplantation
SummaryThe combination of piperacillin with tazobactam (PIP/TAZ) extends the activity of piperacillin against gram-positive, gram… 
2005
2005
[Clinical effects of piperacillin and tazobactam/piperacillin on Haemophilus influenzae lower respiratory tract infection in pediatric patients].
OBJECTIVE The prevalence of beta-lactamase-nonproducing ampicillin-resistant (BLNAR) Haemophilus influenzae (H. influenzae) has… 
1998
1998
[Pharmacokinetic, bacteriological and clinical evaluation of tazobactam/piperacillin in pediatrics].
Pharmacokinetic, bacteriological and clinical studies were performed in pediatrics on tazobactam/piperacillin (TAZ/PIPC), a… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)